Natera, Inc.(NTRA) - Stock detail

Natera, Inc.

US
NTRA
Natera, Inc.(Listing date: 07/02/2015)

Natera, Inc. was incorporated in Delaware in January 2007. The company is a diagnostic company with proprietary molecular and bioinformatics technologies that it is applying to transform disease management worldwide. The company's cell-free DNA (cfDNA) technology combines novel molecular analytical methods that can reliably measure many informative regions across the entire genome from samples as small as a single cell, as well as statistical algorithms that incorporate data provided by the broader scientific community to identify genetic variations covering a wide range of serious diseases with high precision and high coverage. The company's goal is to make personalized genetic testing and diagnosis part of the standard of care for protecting health and inform earlier and more targeted interventions to help achieve longer, healthier lives.

AI Sentiment AnalystBuy
Sentiment Score8/10
Generated At:2026-03-13 17:42:23
Analysis based on 20 news articles from February 19 to March 13, 2026, with most news within 2 weeks of analysis date. Data sources include Yahoo Finance news articles covering product launches, earnings reports, clinical trial results, analyst ratings, and market performance. Data completeness is optimal with no critical lag issues.
News Overview

News impact estimated at +15-20% price upside over medium to long-term, with short-term volatility from macro sensitivity; recommend buying on dips below $210 for growth exposure.

Positive
4
Neutral
0
Negative
1
Event Timeline
2026-03-13
Price Impact: +3-5% short-term, long-term revenue growth
long-term
Natera launched Zenith Genomics on March 13, 2026, addressing a $1 billion U.S. rare disease market by leveraging MyOme's multi-omic platform and Natera's clinical infrastructure, creating new revenue streams and strengthening diagnostic portfolio
2026-03-03
Price Impact: +4-8% immediate impact
immediate
Natera reported Q4 2025 with 40% YoY revenue growth exceeding estimates by +0.76%, net income of $0.35/share vs expected loss of $0.46/share (+175% surprise), and record testing volume, revenue, and gross margin metrics
2026-03-03
Price Impact: +3-5% short-term
short-term
Citi named NTRA its top diagnostics pick on March 11, 2026, signaling institutional confidence, while Canaccord Genuity reiterated Buy rating post-Q4 on March 3, triggering +4.3% stock surge, and retail momentum included NTRA in multiple stocks to target lists
2026-03-01
Price Impact: +2-4% medium-term
medium-term
Positive Phase 2 data for Signatera in head/neck cancer presented at MHNCS 2026 reinforces Natera's oncology leadership and expands addressable markets, supporting long-term growth trajectory
2026-02-27
Price Impact: -5-10% near-term
short-term
Stock fell -8.3% on February 27 due to higher-than-expected PPI inflation data, reflecting macro sensitivity, and declined -10% over past month after 26x 3-year return, suggesting profit-taking and momentum cooling with valuation concerns
News Topics List

Zenith Genomics Launch for Rare Disease Market Expansion

2026-03-13positivePrice Impact: +3-5% short-term, long-term revenue growthlong-term
AI Key Summary
  • Natera's launch of Zenith Genomics represents strategic expansion into rare disease detection
  • Leverages MyOme's multi-omic platform and Natera's clinical infrastructure
  • Addresses approximately $1 billion U.S. rare disease market
  • Potentially captures new revenue streams and strengthens diagnostic portfolio
  • Game changer for Natera's rare disease strategy
Source

Strong Q4 2025 Earnings Exceeding Estimates

2026-03-03positivePrice Impact: +4-8% immediate impactimmediate
AI Key Summary
  • Revenue growth: 40% YoY increase, exceeding estimates by +0.76%
  • Profitability shift: Net income of $0.35/share vs expected loss of $0.46/share (+175% surprise)
  • Record metrics: All-time high testing volume, revenue, and gross margin
  • Earnings beat demonstrates strong operational performance
  • Q4 results show inflection point in profitability
Source

SINERGY Trial Positive Phase 2 Results for Oncology

2026-03-01positivePrice Impact: +2-4% medium-termmedium-term
AI Key Summary
  • Positive Phase 2 data for Signatera in head/neck cancer
  • Presented at MHNCS 2026 conference
  • Reinforces Natera's oncology leadership position
  • Expands addressable markets for Signatera platform
  • Supports long-term growth in cancer diagnostics
Source

Analyst Endorsement and Institutional Confidence

2026-03-03positivePrice Impact: +3-5% short-termshort-term
AI Key Summary
  • Citi named NTRA its top diagnostics pick on March 11, signaling institutional confidence
  • Canaccord Genuity reiterated Buy rating post-Q4, triggering +4.3% stock surge
  • Retail momentum with inclusion in multiple stocks to target lists
  • Analyst sentiment supports growth narrative and investment thesis
  • Multiple positive analyst actions reinforce bullish outlook
Source

Macro Sensitivity and Valuation Concerns

2026-02-27negativePrice Impact: -5-10% near-termshort-term
AI Key Summary
  • Stock fell -8.3% on February 27 due to higher-than-expected PPI inflation data
  • Reflects beta-like reactivity to macroeconomic shifts and inflation concerns
  • Shares declined -10% over past month after 26x 3-year return
  • Suggests profit-taking and momentum cooling after strong rally
  • Valuation concerns emerging after significant price appreciation
Source